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Abstract
To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with
previously untreated advanced non-small cell lung cancer (NSCLC). Methods: A meta-analysis was performed using trials
identified through PubMed, EMBASE, and Cochrane databases. Two investigators independently assessed the quality of the
trials and extracted data. The outcomes included overall survival (OS), progression-free survival (PFS), response rate (RR), and
different types of toxicity. Hazard ratios (HRs), odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled using
RevMan software. Results: Four trials involving 2,518 patients with previously untreated advanced NSCLC met the inclusion
criteria. Pemetrexed plus platinum chemotherapy (PPC) improved survival compared with other platinum-based regimens
(PBR) in patients with advanced NSCLC (HR=0.91, 95% CI: 0.83–1.00, p=0.04), especially in those with non-squamous
histology (HR=0.87, 95% CI: 0.77–0.98, p=0.02). No statistically significant improvement in either PFS or RR was found in
PPC group as compared with PBR group (HR=1.03, 95% CI: 0.94–1.13, p=0.57; OR=1.15, 95% CI: 0.95–1.39, p=0.15,
respectively). Compared with PBR, PPC led to less grade 3–4 neutropenia and leukopenia but more grade 3–4 nausea.
However, hematological toxicity analysis revealed significant heterogeneities. Conclusion: Our results suggest that PPC in
the first-line setting leads to a significant survival advantage with acceptable toxicities for advanced NSCLC patients,
especially those with non-squamous histology, as compared with other PRB. PPC could be considered as the first-line
treatment option for advanced NSCLC patients, especially those with non-squamous histology.
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Introduction
Lung cancer is the leading cause of cancer-related mortality in
both men and women, resulting in approximately 221,130 new
cases and 156,940 deaths within the United States in 2011 [1].
Lung cancer causes approximately 1.3 million deaths per year
worldwide, and non-small cell lung cancer (NSCLC) represents
85% of all lung cancers. The 5-year survival of patients with
metastatic NSCLC is less than 10% [2,3]. Platinum-based doublet
chemotherapy is the current standard of care for patients with
preserved functional status. Patients treated with platinum-based
regimens have a mean survival of 8–10 months. Despite advances
in the treatment of advanced NSCLC, the advent of third-
generation cytotoxic agents including gemcitabine and docetaxel
has reached a therapeutic plateau [4].
Pemetrexed is a multi-targeted inhibitor of three key enzymes in
the folate metabolic pathway: thymidylate synthase (TS), dihy-
drofolate reductase (DHFR) and glycinamide ribonucleotide
formyl transferase (GARFT) [5,6]. In 2008, Scagliotti et al. [7]
compared first-line pemetrexed/cisplatin (PP) to gemcitabine/
cisplatin (GP) and found that pemetrexed was not inferior in terms
of overall survival (OS) (hazard ratio [HR]=0.94, 95% confidence
interval [CI]: 0.84–1.05). However, the result of subgroup analysis
showed that pemetrexed improved OS in patients with non-
squamous histology (adenocarcinoma and large cell carcinoma)
(HR=0.81, 95% CI: 0.70–0.94). Therefore, the pemetrexed-
cisplatin regimen is recommended by the National Comprehensive
Cancer Network (NCCN) guidelines as the first-line treatment for
patients with advanced non-squamous NSCLC [8].
However, in 2009, Gronberg et al [9]. found that pemetrexed/
carboplatin (PC) provided similar OS when compared with
gemcitabine/carboplatin (GC), and that there was also no
difference in OS when analyzing patients with non-squamous
histology (7.8 months versus 7.5 months, p=0.77). Another study
[10] concluded that PC treatment was associated with significantly
longer OS when compared with docetaxel/carboplatin (DC) (12.7
months versus 9.2 months, p=0.05). Hence, the role of the
pemetrexed plus platinum chemotherapy (PPC) in the treatment of
advanced NSCLC remains undefined. The objective of this meta-
analysis was to compare the efficacy and toxicities of PPC with
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37229other platinum-based regimens (PBR) in the treatment of patients
with previously untreated advanced NSCLC.
Methods
Literature Search
An electronic sensitive search of PubMed, EMBASE and
CENTRAL (the Cochrane Central Register of Controlled Trials)
database was performed in December 2011, using the following
key words as the search terms: ‘‘NSCLC’’, ‘‘non-small cell lung
cancer’’, ‘‘pemetrexed or Alimta or LY231514’’, ‘‘first-line’’, and
‘‘chemotherapy-naive’’. Only randomized controlled trials that
fulfilled the criteria of a highly sensitive filter were included in this
study [11]. The published languages and years were not limited.
The relevant reviews and meta-analyses regarding the role of the
first-line treatment for patients with NSCLC were examined for
potential inclusive trials. References of all randomized clinical
trials were scanned for additional study. The American Society of
Clinical Oncology (ASCO) and European Society for Medical
Oncology (ESMO) annual meeting abstracts in the latest 15 years
were also searched.
Selection Criteria
Trials were excluded if they did not meet with the below
inclusion criteria. Trials were included if: (1) they compared PPC
(pemetrexed plus cisplatin or carboplatin chemotherapy) with
other PBR (third-generation agents plus cisplatin or carboplatin
regimens); (2) enrolled NSCLC patients were previously untreated;
and (3) treated patients had stage IIIB or IV NSCLC, regardless of
the publication status (published, conference proceedings, or
unpublished). Two investigators (L.M. and Z.Q.) independently
inspected each reference and applied the inclusion criteria. For
possibly relevant articles or in cases of disagreement, all
investigators inspected the full text independently.
Data Extraction And Quality Assessment
The two investigators independently extracted data from all
primary studies that fulfilled the inclusion criteria, and any
disagreement was resolved by consensus. In articles where
outcomes were not reported, attempts were made to contact the
authors for additional information. The following data were
abstracted from each article with a standardized approach,
including publication details, quality scores, trial characteristics
(such as the number of the patients, chemotherapy regimens, age,
gender, stage, and pathologic type), outcome measures (such as
response rates [RR], HRs for OS and progression-free survival
[PFS] and their 95% CIs, log-rank test p values), and specific grade
3–4 adverse events including hematological and nonhematological
toxicities.
The same reviewers independently assessed trials for method-
ological quality by the Jadad scale [12], and any disagreement was
resolved by consensus. The Jadad score was based on the explicit
description of the study in the text as ‘‘randomized’’ and ‘‘double-
blind’’, and reporting of ‘‘withdrawals and dropouts’’
Statistical Analysis
Data were analyzed using Review Manager (RevMan, Version
5.0, Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2008). Time-to-event data were summarized by the
log HR and its variance using previously reported methods [13].
Results were presented as HRs and 95% CIs using a general
variance-based method. Dichotomous data were compared using
an odds ratio (OR). Respective 95% CI was calculated for each
estimate and presented in forest plots.
Statistical heterogeneity of the trial results was assessed with the
x
2 test for heterogeneity and the I
2 test for inconsistency [14]. If
the p value was less than 0.1 (x
2 test), the results were considered
heterogeneous; if the I
2 was greater than 50%, the results were
Figure 1. Procedures used for trial selection. Abbreviations: RCT, randomized controlled trial.
doi:10.1371/journal.pone.0037229.g001
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were significant, the DerSimonian and Laird random-effects
model was used to analyze the treatment groups. The potential
presence of publication bias was evaluated visually by inspecting
funnel plots and statistically by the Egger’s test [16].
Results
Search Of The Published Literature
The literature search identified 803 publications on pemetrexed,
13 of which were potentially eligible trials that examined
pemetrexed therapy in advanced NSCLC patients. Figure 1 shows
the reasons for excluding 9 of these reports. Ultimately, four trials
were included, all of which were performed between 2008 and
2011, involving a total of 2,518 advanced NSCLC patients
[7,9,10,17]. None of the conference abstracts met the inclusion
criteria and therefore were not included for analysis. Multiple
publications were excluded from the count of included studies
because they were secondary publications of previous reports,
though any relevant and unique results were extracted and
included. The PRISMA Checklist and Flow Diagram for the
studies is shown in Checklist S1 and Figure S1.
Characteristics Of The Included Studies
The quality of the four trials was assessed with the three-question
instrument proposed by Jadad et al. [12]. All the four trials included
statements regarding randomization, and three of the trials
described the detailed methods used for randomization [7,9,17].
Thus, all trials were scored as 1 or 2 based on randomization
criteria. All trials reported withdrawals and drop-outs, but none of
them specified the use of double-blind methodology. Three of the
four trials werephaseIIIRCTs[7,9,17],andthe othertrial[10] was
phase II RCT. Only one trial [7] used cisplatin, and the others used
carboplatin [9,10,17]. Two trials compared pemetrexed to
gemcitabine [7,9], and the other two trials compared pemetrexed
to docetaxel [10,17]. One of the four trials was a three-arm trial
[10]. All the four trials were reported in full text. The baseline
characteristics of the four trials are listed in Table 1.
Overall Survival
All the four trials (comprising 2,518 cases) reported HRs for OS.
Taken together, the HR for OS favored PPC (HR=0.91, 95% CI:
0.83–1.00, p=0.04), without evidence of heterogeneity between the
studies (I
2=0%; p=0.41) (Figure 2). The pooled HR for OS was
performed using the fixed-effort model. The result indicates that
PPC resulted in a slight but significant reduction in the risk of death
(9%) compared with other PBR in advanced NSCLC. In addition,
no publication bias was detected by Egger’s test (p=0.27).
Subgroup analysis was conducted according to the different
drugs used in PBR. Compared with gemcitabine or docetaxel plus
platinum, PPC showed a beneficial trend in terms of OS despite a
lack of statistical significance (HR=0.92, 95% CI: 0.84–1.02,
p=0.11; HR=0.81, 95% CI: 0.62–1.05, p=0.10, respectively)
(Figure 2). There was no evidence of heterogeneity between the
studies (I
2=0%, p=0.50; I
2=34%, p=0.22, respectively). There
was no evidence of statistical interaction between the two
subgroups (p=0.36).
Sensitivity analysis was performed after the trial [7] using
carboplatin was excluded because of the possible difference in
efficacy between platinum agents. The result confirmed the benefit
of PPC (HR=0.85, 95% CI: 0.72–0.99, p=0.04), with no
evidence of heterogeneity (I
2=0%; p=0.42).
Three trials [7,9,17] reported HRs for OS in patients with non-
squamous histology (comprising 1,792 cases). Taken together, PPC
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37229was associated with a clinically and statistically significant 13%
improvement in OS compared with other PBR (HR=0.87, 95%
CI: 0.77–0.98, p=0.02), with no evidence of heterogeneity
(I
2=14%; p=0.31). Sensitivity analysis excluding the trial using
carboplatin [7] did not confirm the above result (HR=0.99, 95%
CI: 0.80–1.22, p=0.90), with no evidence of heterogeneity
(I
2=0%; p=0.69) (Figure 3). Subgroup and sensitivity analyses
excluding the trial using docetaxel [17] also gave a negative result
(HR=0.88, 95% CI: 0.71–1.10, p=0.27), with significant
heterogeneity (I
2=53%; p=0.14).
Progression-free Survival
Two trials [7,17] reported HRs for PFS (comprising 1,936
cases). Compared with other PBR, PFS was not significantly better
in patients who received PPC (HR=1.03, 95% CI: 0.94–1.13,
p=0.57). There was no evidence of heterogeneity between the
studies (I
2=0%, p=0.41) (Figure 4).
Overall Response Rates
Socinski et al. [10] reported both complete and partial responses.
Three trials [7,10,17] reported overall response. Compared with
other PBR, PPC showed a beneficial trend in terms of RR despite a
lack of statistical significance (OR=1.15, 95% CI: 0.95–1.39,
p=0.15). There was no evidence of heterogeneity between the
studies (I
2=30%,p=0.24) (Figure 5).
Toxicity
Hematological Toxicity. Chemotherapy toxicity was de-
scribed as patients experiencing grade 3–4 toxicity. Figure 6 is a
summary of grade 3–4 hematological toxicity. All the four trials
Figure 2. Comparison of overall survival between pemetrexed plus platinum chemotherapy and other platinum-based regimens.
Abbreviations: SE, standard error; IV, inverse variance; CI, confidence interval.
doi:10.1371/journal.pone.0037229.g002
Figure 3. Comparison of overall survival in patients with nonsquamous histology between pemetrexed plus platinum
chemotherapy and other platinum-based regimens. Abbreviations: SE, standard error; IV, inverse variance; CI, confidence interval.
doi:10.1371/journal.pone.0037229.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37229reported hematological toxicity, including neutropenia, anemia
and thrombocytopenia. Only three trials [7,9,17] reported
leukopenia. Compared with other PBR, PPC led to less grade
3–4 neutropenia and leukopenia (OR=0.50, 95% CI: 0.34–0.74,
p=0.0005; OR=0.41, 95% CI: 0.25–0.65, p=0.0002, respec-
tively). Compared with the gemcitabine-based regimen, a statis-
tically significant decrease in thrombocytopenia but not in anemia
was observed (OR=0.28, 95% CI: 0.21–0.37, p,0.00001;
OR=0.72, 95% CI: 0.39–1.34, p=0.30, respectively). Compared
with the docetaxel-based regimen, a statistically significant in-
crease in thrombocytopenia and anemia was observed (OR=5.75,
95% CI: 2.45–13.52, p,0.0001; OR=9.95, 95% CI: 2.94–33.68,
p=0.0002, respectively). The pooled ORs for hematological
toxicity were performed using the random-effort model because
of heterogeneities.
Non-hematological Toxicity
Figure 7 is a summary of grade 3–4 non-hematological toxicity.
All the four trials reported nausea, three trials [7,10,17] reported
vomiting, and two trials [10,17] reported diarrhea. Compared
with other PBR, PPC led to more grade 3–4 nausea (OR=1.63,
95% CI: 1.11–2.39, p=0.01) but not vomiting and diarrhea
(OR=0.98, 95% CI: 0.67–1.44, p=0.92; OR=0.24, 95% CI:
0.05–1.13, p=0.07, respectively). There was no significant
heterogeneity for all the nonhematological toxicity analyses.
Discussion
The current standard first-line treatment for patients with
advanced NSCLC is platinum-based doublets with third-genera-
tion agents (i.e. gemcitabine, paclitaxel, docetaxel, irinotecan and
vinorelbine). A previous meta-analysis [18] by Grossi et al. found
comparable activity between the third-generation regimens in the
first-line treatment of advanced NSCLC. Pemetrexed is a novel
multi-targeted antifolate chemotherapy agent that primarily
inhibits TS. In 2008, Scagliotti et al. [7] first reported a large
phase III study to compare PP with GP, finding that pemetrexed
significantly improved OS in non-squamous patients but signifi-
cantly decreased OS in squamous patients. Based on this study,
pemetrexed has been granted as the first-line treatment for
patients with advanced non-squamous NSCLC. In 2009, Gron-
berg et al. [9] reported another phase III study, but they did not
demonstrate any significant association between histology and
survival. Recently, Rodrigues-Pereira et al. [17] also reported a
negative result. Therefore, we preformed a meta-analysis to
evaluate the efficacy and safety of PPC as the first-line
chemotherapy in patients with advanced NSCLC.
The main finding of the present meta-analysis is that PPC
improved OS homogenously and significantly, when compared
with other PBR, with a 9% reduction in the risk of death. But the
subgroup meta-analysis concerning gemcitabine and docetaxel
failed to show positive benefits in PPC. Although the association
between histology and survival in NSCLC is controversial
[7,9,19], our results show a significant 13% OS improvement in
non-squamous patients treated with pemetrexed. One potential
explanation is that higher TS gene expression in squamous cell
carcinoma compared with adenocarcinoma may confer relative
resistance to pemetrexed [20,21]. There were more non-squamous
patients than squamous patients in the selected four trials (from
70% to 100%), implying that non-squamous patients might play a
greater role in the meta-analysis of OS for all NSCLC patients.
Scagliotti et al. [7] reported reversed results in those with
squamous histology treated with PP (HR=1.22, 95% CI: 0.99–
1.50, p=0.05). However, there are not enough data to perform the
meta-analysis of patients with squamous histology.
Regarding grade 3–4 toxicity data, our pooled analysis showed
that pemetrexed produced less neutropenia and leukopenia, but
more nausea. Subgroup analysis showed that pemetrexed
produced more thrombocytopenia and anemia compared with
docetaxel and less thrombocytopenia compared with gemcitabine.
To the best of our knowledge, this is the first meta-analysis
to evaluate the efficacy and safety of PPC as the first-line
Figure 4. Comparison of progression-free survival between pemetrexed plus platinum chemotherapy and other platinum-based
regimens. Abbreviations: SE, standard error; IV, inverse variance; CI, confidence interval.
doi:10.1371/journal.pone.0037229.g004
Figure 5. Comparison of response rate between pemetrexed plus platinum chemotherapy and other platinum-based regimens.
Abbreviations: M-H, mantel-haenszel; CI, confidence interval.
doi:10.1371/journal.pone.0037229.g005
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random phase II trials showed that pemetrexed plus platinum
regimens were associated with median survival times of 8.9 to 13.5
months and RRs of 24% to 45.8% [22,23,24] However,
comparing with other PBR, our results of four RCTs demonstrat-
ed that pemetrexed regimens could improve OS in advanced
NSCLC patients, especially in non-squamous NSCLC patients,
but not PFS and RR, and PPC was well tolerated with less
neutropenia and leukopenia but more nausea. Recently, a
combined analysis by Treat et al. [25] also showed that PP was
associated with favorable survival when compared with GP in non-
squamous NSCLC patients but not in all patients.
There were several limitations in our study. First, as there were
only four RCTs and some data were not reported, these results
need to be interpreted very cautiously. As only non-squamous data
were available for analysis while other data such as HRs for OS
based on squamous histology, gender and age were not mentioned
in most studies, further analysis of individual patient data is needed
to confirm our findings. Second, although publication bias was not
found according to funnel plots and Egger’s test, the small number
of trials and possible existence of unpublished studies limited the
power of these tests. Furthermore, the method used to calculate
HRs and different covariates used for HRs adjustment may lead to
potential bias. We calculated HR, log HR, and its variance from
the data or the survival curves included in the article. In addition,
HRs in the studies were adjusted for different covariates, and
covariates were not consistent even in multivariate analysis
performed in different studies. Third, because this study is based
on the trials of gemcitabine and docetaxel, the results are not
necessarily applicable to treatments that use other drugs.
Subgroup analysis showed negative results for OS in gemcita-
bine-based trials. Fourth, our results were pooled from four RCTs
of chemotherapy in advanced NSCLC. However, erlotinib
conferred a significant progression-free survival benefit in patients
with advanced EGFR mutation-positive NSCLC [26]. Although
mutational profiling has not yet been widely adopted into practice,
customizing targeted therapies to specific mutations may be more
effective for some types of cancer [27]. Therefore, the conclusions
should be applied to patients unsuitable for targeted therapy.
Finally, our results were inconsistent with other studies. Treat et al.
[25] also reported that no significant benefit for OS was observed
in all patients or non-squamous patients treated with PP, when
Figure 6. Summary of grade 3–4 hematological toxicity. Abbreviations: M-H, mantel-haenszel; CI, confidence interval.
doi:10.1371/journal.pone.0037229.g006
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37229compared with GC, gemcitabine/paclitaxel, and paclitaxel/
carboplatin. Therefore, more trials comparing PPC with PBR
are needed to evaluate the efficacy of pemetrexed in chemother-
apy-naive advanced non-squamous NSCLC patients.
In conclusion, this meta-analysis demonstrates that PPC in the
first-line setting leads to a significant survival advantage for
advanced NSCLC patients and non-squamous patients compared
with other PBR. Taking into account less toxicity (such as
neutropenia and leukopenia), PPC could be considered as the first-
line treatment option for patients with advanced NSCLC,
especially those with non-squamous histology.
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